Search for: "In re Cipro Cases"
Results 41 - 60
of 78
Sorted by Relevance
|
Sort by Date
10 Jan 2011, 5:54 am
(Case No. 10-762). [read post]
11 Jan 2011, 1:51 pm
(In re Tamoxifen Citrate Antitrust Litig.), 2006-2 Trade Cases ¶75,382. [read post]
24 Dec 2011, 5:31 am
(See In re Cipro Cases I & II (2004) 121 Cal. [read post]
13 Oct 2009, 1:33 pm
In In Re Cipro, 2008-1097 (Fed. [read post]
15 Sep 2010, 2:40 am
Highlights this week included: 2nd Circuit denies en banc reconsideration in Cipro case: In re Ciprofloxacin Antitrust Litigation (Patent Docs) (FDA Law Blog) (IPBiz) Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored. [read post]
2 Oct 2009, 8:35 pm
Of these resistant isolates, 90% also showed decreased susceptibility to cipro (7). [read post]
17 Oct 2008, 1:32 pm
Proposed EU information laws on prescription drugs (IPmed) Iceland: Supplementary Protection Certificates (SPCs) in Iceland (The SPC blog) India: Roche implements 'mass serialisation' anti-counterfeiting technology (Spicy IP) Indonesia: Patent application on oil palm hybrids (navigating the patent maze) United States: New PMCA research: State legislative proposals restricting access to generic medicines would increase cost $29 billion over 10 years (GenericsWeb) US: Pharmaceutical… [read post]
10 Sep 2012, 3:48 pm
Brand names for this class include Cipro, Levaquin and Avelox. [read post]
29 Aug 2012, 10:09 pm
As we previously reported, the case, styled as In re Cipro Cases I & II, was initiated in late 2000 and is a proceeding of nine coordinated cases brought by indirect CIPRO purchasers. [read post]
9 Sep 2009, 7:14 am
(America-Israel Patent Law) Avinza (Morphine) – US: King Pharmaceuticals, Elan files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs) Cipro (Ciprofloxacin) – US: California court rules that Bayer AG et al did not violate state antitrust law in Cipro reverse payment case (FDA Law Blog) Effexor (Venlafaxine) - Israel: Patent oppositions: should substance or procedural issues win out? [read post]
1 May 2012, 6:49 pm
In the end, however, the full court did not vote to rehear the Cipro case en banc. [read post]
23 May 2011, 1:54 pm
Court of Appeals for the Third Circuit in In Re K-Dur Antitrust Litigation, Case Nos. 10-2077, 10-2078, 10-2079. [read post]
15 Jan 2010, 7:55 am
Of these resistant isolates, 90% also showed decreased susceptibility to cipro (7). [read post]
4 Jan 2010, 3:39 pm
Of these resistant isolates, 90% also showed decreased susceptibility to cipro (7). [read post]
17 Oct 2013, 5:00 am
In re TFT-LCD Antitrust Litigation / Direct Purchasers Class v. [read post]
10 Jun 2010, 10:41 am
Court of Appeals for the Second Circuit in In re: Ciprofloxacin Hydrochloride Antitrust Litigation. [read post]
27 May 2010, 3:20 am
(Patent Docs) Cipro (Ciprofloxacin)- Cipro patent settlement case appealed to the California Court of Appeal: In re Ciprofloxacin Antitrust Litigation (FDA Law Blog) (Patent Docs) Fluvastatin - Spain: Interim injunctive relief in Spain – Novartis (PatLit) Intuniv (Guanfacine) – US: Patent infringement complaint based on ANDA filing: Shire LLC et al. v. [read post]
25 Oct 2008, 12:03 am
Sandoz, Inc (Law360) (Hal Wegner) (Patently-O) (Patent Prospector) (PLI) Cipro (Ciprofloxacin) - US: CAFC finds no antitrust liability for Hatch-Waxman reverse payment settlements: In Re Ciproflaxacin Hydrochloride Antitrust Litigation (IP Law Observer) Lescol (Fluvastatin) - US: Mylan confirms first-to-file patent challenge to Lescol by Novartis (SmartBrief) Levaquin (Levofloxacin) - UK: Levofloxacin SPC valid: Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd & Anor… [read post]
15 Dec 2010, 2:17 am
Becton, Dickinson & Co (Intellectual Property Law Blog) US: Regents of the University of California pursue new patent re-examination in District Court (Patents Post Grant Blog) US: Microsoft v i4i, the burden of proof and the pharma sector (PatLit) US: IRS issues notice to implement annual fee on brand drugs (FDA Law Blog) US: Bright ‘orphan’ ideas blossom (FDA Law Blog) US: Amicus briefs in AMP v USPTO (Patent Docs) (Patent Docs) (Patent Docs) US: University of California… [read post]
12 Aug 2009, 5:08 pm
" In its Cipro brief, the DOJ initially took note of the unique characteristics of the pharmaceutical industry leading to the prevalence of reverse payment settlements -- settlements which the DOJ further noted are virtually nonexistent in other contexts. [read post]
